You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Medtronic
Merck
Boehringer Ingelheim
Harvard Business School

Last Updated: April 6, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,507,800

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,507,800
Title:Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
Abstract: The present invention relates generally to the field of human genetics, and more specifically to the detection of a specific type of germline mutations in the BRCA1 gene, which will predispose to breast and ovarian cancer. In addition, the invention relates to the molecular genetic mechanism that may have mediated the genesis of these mutations, in particular the role of Alu repetitive DNA elements present in the intronic regions of BRCA1. The invention further relates to somatic mutations of this type in the BRCA1 gene in human breast and ovarian cancer, and their use in the diagnosis and prognosis of human breast and ovarian cancer. The invention more particularly relates to the screening of this type of BRCA1 mutations in human genomic DNA, which are useful for the diagnosis of inherited predisposition to breast and ovarian cancer.
Inventor(s): van Ommen; Garrit-Jan Boudewijn (Amsterdam, NL), Petrij-Bos; Anne (Leiden, NL), Bakker; Egbert (Leiden, NL), Devilee; Peter (Leiden, NL)
Assignee: Rijksuniversiteit te Leiden (Leiden, NL)
Application Number:10/654,382
Patent Claims:1. A labeled probe for detecting a deletion of a stretch of nucleotides from a BRCA1 gene, wherein said deletion consists of: a. exon 22, b. nucleotides 1396-1662, c. exons 13 through 16, d. exon 13, e. an exon 22 deletion that starts in intron 21 and ends in intron 22, or f. an exon 13 deletion that starts in intron 12 and ends in intron 13 wherein the probe is a fusion product of two nucleic acid sequences adjacent to the deletion that is capable of detecting the deletion.

2. A diagnostic test kit for detecting a predisposition for breast and ovarian cancer, comprising a labeled probe for detecting a deletion of a stretch of nucleotides from a BRCA1 gene, wherein the labeled probe consists of: a. a sequence specific for detecting a deletion consisting of exon 22, b. a sequence specific for detecting a deletion consisting of nucleotides 1396-1662, c. a sequence specific for detecting a deletion consisting of exons 13 through 16, d. a sequence specific for detecting a deletion consisting of exon 13, e. a sequence specific for detecting a deletion consisting of an exon 22 deletion that starts in intron 21 and ends in intron 22, or f. a sequence specific for detecting a deletion consisting of an exon 13 deletion that starts in intron 12 and ends in intron 13 wherein the probe is a fusion product of two nucleic acid sequences adjacent to the deletion that is capable of detecting the deletion.

3. A diagnostic test kit according to claim 2, comprising at least two of a, b, c, and d.

4. A diagnostic test kit according to claim 2, comprising at least four of a, b, c, and d.

5. A diagnostic test kit for detecting a predisposition for breast and ovarian cancer, comprising labeled probes for detecting in a sample the presence of a nucleic acid derived from a BRCA1 gene having a deletion, wherein the probes comprise at least two of the following: a. a labeled sequence specific for either side of a deletion consisting of exon 22, b. a labeled sequence specific for either side of a deletion consisting of nucleotides 1396-1662, c. a labeled sequence specific for either side of a deletion consisting of exons 13 through 16, d. a labeled sequence specific for either side of a deletion consisting of exon 13, e. a labeled sequence specific for a deletion consisting of an exon 22 deletion that starts in intron 21 and ends in intron 22, or f. a labeled sequence specific for a deletion consisting of an exon 13 deletion that starts in intron 12 and ends in intron 13.

6. A diagnostic test kit according to claim 2, comprising at least three of a, b, c, and d.

7. A diagnostic test kit according to claim 2, comprising at least four of a, b, c, and d.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
97201700Jun 4, 1997

Details for Patent 7,507,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Rijksuniversiteit te Leiden (Leiden, NL) 2017-06-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Rijksuniversiteit te Leiden (Leiden, NL) 2017-06-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Rijksuniversiteit te Leiden (Leiden, NL) 2017-06-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Moodys
Mallinckrodt
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.